“Choosing where you go is so, so, so important.” Lung cancer patient Oswald chose to receive care at a teaching hospital where doctors were not only aware of cutting-edge immunotherapies but are often directly involved in clinical and scientific research. #CIM21 #Immune2Cancer #CancerStory
On New Year’s Day 2017, Oswald woke up extremely sick. After a week of illness and wanting the best care possible, he left Brooklyn and went to Columbia University Medical Center where he was diagnosed with stage 4 non-small cell lung cancer. With a PD-L1 score of 80 percent, he was eligible for a newly approved first-line treatment with pembrolizumab (Keytruda®), PD-L1 checkpoint immunotherapy. Almost immediately, he felt different; today, he has no evidence of disease. Now, every day is like a New Year’s Day for Oswald, and he looks forward to dancing in Trinidad's Carnival next year. [ Ссылка ]
This video is part of the 9th Annual Cancer Immunotherapy Month™ in June 2021, hosted by the Cancer Research Institute. Help us raise awareness of the lifesaving potential of immunotherapy for all types of cancer. Let's fuel the next scientific discoveries and breakthrough treatments through learning, engagement, and storytelling. [ Ссылка ]
Immunotherapy patient stories are part of the Cancer Research Institute's Answer to Cancer Patient Education Program. Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. [ Ссылка ]
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.
